Coulon has more than 20 years of sales, marketing and business development experience within the pharmaceutical industry. Although his background includes a broad list of therapeutic specialities, his strength is in ocular drug development.
Coulon has previously worked at Ciba Vision (Novartis), Akorn, Mallinckrodt Pharmaceuticals, Stonebridge Pharma (GSK), Auriga Laboratories and CCG Partners.
PharmOptima appoints business development director
Ophthalmology specialist hires Rick Coulon
You may also like
Research & Development
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Research & Development
Evotec secures $2.9m grant to advance stem cell-based drug safety testing
The three-year Gates Foundation grant will support Evotec's human induced pluripotent stem cell platform, helping global health researchers identify potential developmental toxicity risks earlier in drug discovery
Research & Development
TUM develops GNExT platform to identify potential Alzheimer’s drug candidates
The Technical University of Munich has developed a web-based tool that connects genome-wide association study data with biological networks, helping researchers identify disease mechanisms and potential drug repurposing opportunities